Aug. 27 (Bloomberg) -- Actelion Ltd., the Swiss drugmaker that gets almost 90 percent of sales from a treatment for a rare lung disease, said Andre Muller will replace Chief Financial Officer Andrew Oakley, who is leaving the company.
Muller, 49, will start the position on Sept. 1, the Allschwil-based company said in a statement today. Oakley, 51, is leaving to “focus on opportunities outside Actelion,” the drugmaker said.
Muller is moving from Pierre Fabre SA, a maker of pharmaceuticals and cosmetics, where he held the same position. Oakley has been CFO of Actelion for 10 years.
Actelion raised its full-year profit forecast in July as second-quarter sales beat estimates and it cut spending. The improved outlook may renew takeover speculation, Andrew Weiss, an analyst at Bank Vontobel AG in Zurich, said at the time.
To contact the reporter on this story: Thomas Mulier in Geneva at email@example.com
To contact the editor responsible for this story: David Risser at firstname.lastname@example.org